BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation ...
If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the ...
Takeda and Protagonist Therapeutics have submitted a new drug application to the FDA for rusfertide for adults with ...
European Space Agency (ESA) astronaut Thomas Pesquet removes the Protein Crystallization Facility hardware from an incubator ...
The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...
Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction ...
Novel immunotherapy combination regimen brings together two complementary therapies to improve outcomes for people living with multiple myeloma as early as second line1 ...
On Monday evening, the Food and Drug Administration approved Novo Nordisk’s high-dose oral formulation of semaglutide for obesity. In clinical trials, people taking the pill lost substantially more ...
The FDA granted accelerated approval to Lunsumio VELO for adults with relapsed/refractory follicular lymphoma after two or more prior treatments. The U.S. Food and Drug Administration (FDA) has ...
Pharmaceutical Technology on MSN
Arrowhead receives Health Canada authorisation for Redemplo to treat FCS
Arrowhead Pharmaceuticals has received authorisation from Health Canada for its small interfering RNA (siRNA) medicine, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback